The FDA’s 2023 decision to maintain the restrictions was unlawful under the Administrative Procedure Act, “by failing to provide a reasoned explanation for its restrictive treatment of the drug,” U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback